Tolero Pharmaceuticals in the Daily Herald
April 29, 2018
This concept is based on the idea that drugs can be more effective once doctors know whether or not they will be right for specific patients. “It’s the right drug for the right patient for the right disease,” said Kelly Slone, president and CEO of BioUtah.
Tolero has already seen success testing this type of drug for treating acute myeloid leukemia. As Tolero Pharmaceuticals CEO David Bears said, “Now what we’re trying to do is develop a drug, and we say, ‘this drug isn’t for everybody, but we have a way to tell whether it’s for you.’ I want to see my discoveries move into something that can help people, that’s motivating to me, thinking I can help people with something I’ve discovered in our lab.”
Click here to read the full article
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
